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Introduction-Over the past decade, several advances have been made in the management of tachycardias by pacing techniques, but limited data are available on the long-term outcome of patients treated with antitachycardia pacemakers.
Patients and methods-An antitachycardia pacemaker, the Intermedics Intertach, was implanted in 22 (17 female) patients with supraventricular tachycardia over a five year period. All were selected after detailed evaluation and testing of a temporary antitachycardia pacemaker system showed that their arrhythmia could be stopped promptly, reliably, and under different physiological conditions.
Results-The 22 patients have been followed up for a mean period of 57 3 (range 19-76) months. All except one of the patients has had frequent episodes of tachycardia reliably ended by the pacemaker. Complications have occurred in seven patients, necessitating removal of the pacing system in four. Of the 18 patients who continue to have pacemakers, seven are being treated with p1 blockers or verapamil; no other antiarrhythmic drugs are being taken.
Conclusions-Antitachycardia pacing is an acceptable long-term option for carefully selected patients with supraventricular tachycardia, but even after extensive testing a substantial number of the patients may continue to require drug treatment. Furthermore, the widespread use of curative techniques for supraventricular arrhythmias (catheter ablation and surgery) has decreased the need for this palliative treatment. The finding that a characteristic of reentrant tachycardia is its ability to be terminated by premature stimuli has been used to develop permanent antitachycardia pacemakers. 1 TERMINATION OF TACHYCARDIA Table 3 shows some of the programmed characteristics of 18 patients being followed up. In all but two cases, the primary antitachycardia response is a burst of four to eight beats, at a cycle length of 75%-90% of the tachycardia cycle; if the tachycardia persists, the burst is repeated at progressively shorter cycles (decremental scanning). In patients 7 and 13, the primary antitachycardia response was a burst of eight or 10 beats during which the pacing cycle length gradually shortened (autodecremental burst pacing).
In all but three patients, a secondary mode was programmed to come into effect if the primary mode was unsuccessful. In 11 patients, this consisted of a train of stimuli slightly longer or faster than the primary response, with decremental scanning as before, in four patients the secondary mode consisted of autodecremental pacing. The frequency column in It is notable that all four of these patients had had at least one previous antitachycardia pacemaker inserted, all four had pacemaker related problems (venous thrombosis in two, wound dehiscence in one, and possible chronic infection in one), and all four had at least one ventricular lead in situ from the previous pacemaker(s). Also of note is the fact that three of these four patients had accessory pathways, and the pacemaker was removed at the time of surgical ablation of the accessory pathway. In part this represents our willingness to replace the palliative treatment of antitachycardia pacing with the curative treatment of surgery in these patients with complications.
SENSING ALGORITHMS AND PACING MODALITIES
The choice of a suitable algorithm for sensing a particular patient's tachycardia depends on the rate of the tachycardia or tachycardias to be treated, the maximum rate of sinus tachycardia, and whether there is any overlap between them, the circumstances that induce the tachycardia (for example exercise, when the sinus rate is rapid), and whether the patient is prone to other arrhythmias that the pacemaker should not attempt to overdrive (for example atrial fibrillation). With the pacemaker used in this series, a combination of four detection features (high rate, sudden onset, rate stability, sustained high rate) can be programmed independently. There are no published studies that have attempted to find the best tachycardia detection algorithm, mainly because the suitability of a particular algorithm will vary between patients, and may also vary within one patient depending on factors such as concomitant drug treatment, changes in arrhythmia substrate or autonomic tone, and development of new arrhythmias. Choice of detection algorithm therefore depends on the characteristics of the individual patient, and can perhaps be helped by exercise testing (to determine the maximum sinus rate on exercise) and spontaneous recordings of the onset of the clinical arrhythmia. Although it has been suggested that the rate stability variable may be helpful in discriminating between a regular supraventricular tachycardia and atrial fibrillation, this hypothesis was not tested in our patients, and it seems likely that the rate of the sensed atrial electrogram during atrial fibrillation would be more rapid than the maximum programmed pacing rate of the pacemaker. In our series most patients had a detection algorithm that required two or more criteria to be satisfied (one of them of necessity being high rate) before the pacemaker would attempt to terminate the tachycardia. The high rate criterion alone was used in three patients. We did not find a particular algorithm to be better than the others-on the contrary, the algorithms chosen were tailored to each individual patient. This obviously added to the time spent on initial assessment and follow up of the patients.
Similarly, the program used for antitachycardia pacing in each patient must be decided on an individual basis, and should ideally be based on the success of a number of trials to end tachycardia, not only in the electrophysiology laboratory, but also as the patient is sitting, standing, and exercising. We believe that our protocol before implantation provides the optimum basis for evaluating each patient and for finding which sensing and pacing modes are most appropriate for each patient. As antitachycardia pacing is a palliative rather than a curative form of treatment, the patients continue to experience paroxysmal tachycardia, albeit of short duration, before the pacemaker can terminate it. Hypotension at the onset of tachycardia, which can be profound when the patient is standing, may produce severe symptoms. The testing before implantation was undertaken to provide reassurance that residual symptoms associated with the onset of tachycardia under different physiological conditions would be acceptable.
There have been several trials of different modes of antitachycardia pacing. Holt et al used the Siemens-Elema Tachylog to assess the relative efficacy of burst pacing, self searching, and adaptive scanning techniques.9 They found that burst pacing was the most effective method, although it was more likely to induce unwanted arrhythmias such as atrial fibrillation. Nathan et al compared autodecremental with fixed rate atrial pacing in 20 patients with supraventricular tachycardia, and found that a five second burst of autodecremental pacing was successful in every case, and less likely to induce atrial flutter or fibrillation than fixed rate bursts.10 Charos et al have shown that autodecremental pacing is more likely to be effective than scanning burst pacing, with a constant cycle length within the burst and a programmed change in burst cycle length at subsequent attempts."I den Dulk et al have described an adaptive pacing mode with an automatically increasing number of stimuli, which they describe as a universal pacing mode. ' 
